Why Centene’s CFO transition matters for shareholders

Centene (CNC) has set out a multi year finance leadership transition after Chief Financial Officer Drew Asher announced plans to step down at the end of 2026, with Chris Neczypor appointed as successor CFO.

The CFO succession news hit a stock that has already had a strong run, with Centene’s share price returning 54.16% year to date but easing recently, shown by the 3.06% 30 day share price decline and 3.24% 7 day pullback. Over a longer horizon, total shareholder return of 122.18% over one year contrasts with broadly flat 3 and 5 year total shareholder returns. This suggests that recent momentum is still working through how investors view Centene’s risk and growth profile after a sharp rebound.

If leadership changes at Centene have you thinking about where else the market is re-rating future growth and risk, this is a good moment to scan 40 healthcare AI stocks.

After a 1 year total shareholder return above 100% and a recent pullback, Centene now forces a choice: lock in exposure after the run, or wait in case the new CFO era lines up with a better entry point.

Most Popular Narrative: 1% Overvalued

Centene’s most followed valuation narrative pegs fair value at about $63.78, just under the recent $64.41 close, which points to a tight valuation gap.

Analysts are assuming Centene's revenue will grow by 4.0% annually over the next 3 years. Analysts assume that profit margins will increase from -3.6% today to 1.3% in 3 years time.

The fair value story for Centene hinges on steady top line growth, a swing into profitability, and a future earnings multiple that differs from today’s loss making status. The crucial pieces are how fast margins rebuild and what earnings power that supports. The narrative sets out clear targets. The question is how those assumptions fit with your own expectations.

Result: Fair Value of $63.78 (OVERVALUED)

However, the Centene narrative also faces pressure from uncertain Medicaid rate decisions and rising specialty drug costs, which could strain margins and challenge current valuation assumptions.

Another view on Centene’s valuation

The SWS DCF model presents a very different picture compared with the “1% overvalued” narrative. On this approach, Centene at $64.41 is described as trading well below an estimated future cash flow value of $189.60, which frames the stock as heavily undervalued. Which perspective do you feel better reflects the risks around Medicaid, Medicare and commercial growth?

Next Steps

With Centene’s valuation narratives pulling in different directions, it helps to move quickly, check the underlying data and decide what matters most to you. To weigh both the optimism and the concerns around this stock side by side, start by reviewing the 3 key rewards and 1 important warning sign.

Looking for more Centene sized investment ideas?

If Centene’s story has sharpened your thinking, do not stop here. Use this moment to scan fresh ideas that might better match your goals.

• Target potential mispricings by reviewing companies flagged in the 53 high quality undervalued stocks.
• Protect your downside by checking out the 80 resilient stocks with low risk scores.
• Get ahead of the crowd by finding future standouts through the screener containing 19 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.